Autoimmune diseaseImmunology & inflammationDermatologyMusculoskeletal diseaseRare disease PKPDExposure-response

Dazukibart IFN-beta and dermatomyositis response

Reference paper ↗

A PK/PD exposure-response model linking intravenous dazukibart disposition and IFN-beta binding to delayed changes in cutaneous, muscle, functional, and global disease assessments.

Therapeutic
Dazukibart
Modality
Other biologic or therapeutic modality
Target
IFNB1, interferon-beta
Disease
Dermatomyositis
Model type
PKPD, Exposure-response

Complete model workspace

Checking workspace access…

Parameters
36
States
15
Equations
15
Derived outputs
149

Explore this model

Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.

Stage 1 600 mg IV every 4 weeks x3

How does dazukibart exposure alter free IFN-beta and the time course of dermatomyositis response measures? Explore this intervention regimen through Dazukibart concentration, Free IFN-beta, CDASI activity response, MMT-8 response, Physician global response.

Starting result

This result reflects the starting settings. Run your changes to update it.

Result preview could not load

The generated result could not be loaded. The inputs remain available below.

Starting configuration

Time: 0–12 week; step 0.25

InputDefaultAvailable range
Systemic clearance1.131 L/week0.5653–1.696 L/week
Central distribution volume3.05 L1.525–4.575 L
Absorption rate constant1.781 1/week0.8904–2.671 1/week
Quasi-steady-state binding constant80.2 pM40.1–120.3 pM
Turnover loss rate0.245 1/week0.1225–0.3675 1/week

Expected readouts

Dazukibart concentration · Free ifn beta · Cdasi activity response (dimensionless) · Mmt 8 response (dimensionless) · Physician global response (dimensionless)

Adjustable model parameters

This public explorer exposes 5 curated parameters. Sign in to edit all 36 declared model parameters.

More key parameters (1)

How the model represents the biology

A PK/PD exposure-response model linking intravenous dazukibart disposition and IFN-beta binding to delayed changes in cutaneous, muscle, functional, and global disease assessments.

How does dazukibart exposure alter IFN-β availability and delayed disease assessments?Intravenous dazukibart enters a central pool, exchanges with a peripheral pool, and undergoes clearance. Central concentration determines an algebraic IFN-beta bound fraction, whose unbound complement drives separate delayed turnover responses for cutaneous, muscle, functional, and global assessments.BIOLOGY OVERVIEWHow does dazukibart exposure alter IFN-β availability and delayed diseaseassessments?IV dazukibartInfusion to central antibodyCentral exposureDazukibart concentrationPeripheral poolReversible distributionDazukibart clearanceCentral concentration lossIFN-β bound fractionAlgebraic exposure-dependentbindingUnbound-IFN driveOne minus bound fractionDisease assessmentsSeparate delayed turnoverendpointsPRIMARY READOUTSCentral dazukibart concentrationCentral dazukibart concent…Free IFN-βFree IFN-βCutaneous scoreCutaneous scoreMuscle scoreMuscle scoreGlobal assessmentGlobal assessment

Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.

Model scope: Receptor signaling, immune-cell mechanisms, a shared latent disease state, binding-mediated drug clearance, and direct clinical benefit are not represented; assessment states are separate empirical responses.

Modeled relationships (6)
  • IV dazukibart → Central exposure: IV input (flow)
  • Central exposure ↔ Peripheral pool: distribution (reversible exchange)
  • Central exposure → Dazukibart clearance: systemic CL (loss)
  • Central exposure → IFN-β bound fraction: sets bound fraction (modulation)
  • IFN-β bound fraction → Unbound-IFN drive: unbound complement (modulation)
  • Unbound-IFN drive → Disease assessments: endpoint turnover (modulation)

Modeled relationships: IV dazukibart to Central exposure: IV input (flow); Central exposure reversibly exchanges with Peripheral pool: distribution (reversible exchange); Central exposure to Dazukibart clearance: systemic CL (loss); Central exposure to IFN-β bound fraction: sets bound fraction (modulation); IFN-β bound fraction to Unbound-IFN drive: unbound complement (modulation); Unbound-IFN drive to Disease assessments: endpoint turnover (modulation).

Primary readouts: Central dazukibart concentration; Free IFN-β; Cutaneous score; Muscle score; Global assessment.

Found a scientific issue? Email helpdesk@unibiointelligence.com with model ID prybylski_2026_dazukibart_ifnb_dm_er.

Research use only — not for patient-specific prediction or dosing advice.

Ubi Biologics